Aptamer Group Secures Licensing Deal with Global Life Sciences Leader
Why we think this is good
The agreement with a leading global life sciences company to develop and license Aptamer's Optimer®-Fc technology is a positive development for the company. The fully funded development work, royalty structure, and potential for commercial launch within the current calendar year suggest a clear path to revenue generation. While some details are still unclear, the partnership with an industry leader and the recurring revenue potential are strong indicators of the agreement's value.
Key Points
- New development and licensing agreement with a global life sciences leader
- Aptamer to develop a custom Optimer®-Fc reagent for use in IHC assays and diagnostic kits
- Partner to fully fund the development work, expected to be completed within 12 months
- Aptamer to receive royalties of 2% on net sales of all assay kits containing the licensed Optimer®-Fc reagent
- Product launch of the IHC kits expected within the current calendar year
Summary
Aptamer Group has announced a new development and licensing agreement with an established global company in the life sciences and diagnostics sector. Under the agreement, Aptamer will develop a custom Optimer®-Fc reagent for use in immunohistochemistry (IHC) assays and diagnostic kits, which the partner will fully fund. Subject to development and validation, the Optimer®-Fc reagent is anticipated to be incorporated into commercial IHC kits, with a product launch expected within the current calendar year. The agreement includes a commercial licensing arrangement, under which Aptamer will receive royalties of 2% on net sales of all assay kits containing the licensed Optimer®-Fc reagent.